Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone.

Slides:

Advertisements

Similar presentations

JNC 7 血壓分期. 血壓分期 JNC 7 ： 1. 增加高血壓前期 2.Stages 2 及 3 高血壓被合併 JNC 7, 2003.

Advertisements

Date of download: 5/28/2016 From: New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study Ann Intern Med. 2012;156(8):

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Diagnoses and Timing of 30-Day Readmissions After.

Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.

Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Quality of Care of and Outcomes for African Americans.

Date of download: 6/18/2016 From: Treatment of Anemia in Patients With Heart Disease: A Systematic Review Ann Intern Med. 2013;159(11): doi: /

Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.

Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Prognosis of Acute Kidney Injury After.

Date of download: 6/25/2016 From: Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2013;159(4):

Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Trends in Anemia Care in Older Patients Approaching.

Date of download: 7/1/2016 From: Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2015;162(4):

Date of download: 7/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Fibroblast Growth Factor 23 and Risks of Mortality.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Intermittent vs Continuous Proton Pump Inhibitor.

Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.

Volume 82, Issue 12, Pages (December 2012)

From: Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseA Systematic Review and Meta-analysis Ann Intern Med. 2012;157(4):

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 American Medical Association. All rights reserved.

Copyright © 2011 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved.

Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.

Copyright © 2003 American Medical Association. All rights reserved.

Ann Intern Med. 2000;133(6): doi: / Figure Legend:

Copyright © 2011 American Medical Association. All rights reserved.

Copyright © 2014 American Medical Association. All rights reserved.

Copyright © 2008 American Medical Association. All rights reserved.

Copyright © 2000 American Medical Association. All rights reserved.

Copyright © 2006 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2004 American Medical Association. All rights reserved.

Copyright © 2013 American Medical Association. All rights reserved.

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2002 American Medical Association. All rights reserved.

Copyright © 2014 American Medical Association. All rights reserved.

Copyright © 2006 American Medical Association. All rights reserved.

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2008 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.

Copyright © 2004 American Medical Association. All rights reserved.

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Step Care Therapy for Hypertension in Diabetic Patients

Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks Sripal Bangalore, MD, MHA, Gbenga Ogedegbe,

Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus George L. Bakris, MD Mayo Clinic.

Volume 82, Issue 12, Pages (December 2012)

Fig. 2. Evidence-based medication prescriptions

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Table of Contents Why Do We Treat Hypertension? Recommendation 5

Volume 80, Issue 9, Pages (November 2011)

Volume 94, Issue 3, Pages (September 2018)

Volume 72, Issue 12, Pages (December 2007)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

by Ali Albasri, Suman Prinjha, Richard J McManus, and James P Sheppard

Statin Use and Risk of COPD Exacerbation Requiring Hospitalization

by Ali Albasri, Suman Prinjha, Richard J McManus, and James P Sheppard

The future of renoprotection: Frustration and promises

Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease C.P. Kovesdy, S. Ahmadzadeh,

Volume 81, Issue 7, Pages (April 2012)

Volume 73, Issue 5, Pages (March 2008)

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

Juan Jesús Carrero, PhD American Journal of Kidney Diseases

(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.

β-Blocker Use for the Stages of Heart Failure

Michael Kreuter, MD, David J

Presentation transcript:

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia JAMA Intern Med. 2014;174(3): doi: /jamainternmed Flowchart of Patient SelectionCKD indicates chronic kidney disease; ESA, erythropoiesis-stimulating agent. a Includes angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, α-blockers, β-blockers, calcium channel blockers, and diuretics. Figure Legend:

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia JAMA Intern Med. 2014;174(3): doi: /jamainternmed Cumulative Hazards of Study Outcomes Among Patients With Predialysis Stage 5 Chronic Kidney DiseaseA, Long-term dialysis. B, Composite outcome of long-term dialysis or death. We used the Nelson-Aalen method to calculate the cumulative hazards of both outcomes in users and nonusers of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin II receptor blockers (ARBs). A multivariate analysis was adjusted for all variables listed in Table 1. P <.001, users vs nonusers. Figure Legend:

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia JAMA Intern Med. 2014;174(3): doi: /jamainternmed Adjusted Hazard Ratios (HRs) of Study Outcomes Among Patients With Predialysis Stage 5 Chronic Kidney DiseaseOutcomes include long-term dialysis and the composite outcome of long-term dialysis or death associated with use of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin II receptor blockers (ARBs). Each factor was adjusted for all other factors listed in Table 1. CCB indicates calcium channel blocker; CHD, coronary heart disease. Figure Legend: